XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million

Reuters

2025/11/12

XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million

XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582376301"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582376301\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582376301?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582376301","market":"us","top_or_hot":-1,"title":"XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of <a href=\"https://laohu8.com/S/TSBX\">Turnstone Biologics</a> and HilleVax, announced acquisitions of LAVA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and <a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a>, and acted as structuring agent for XenoTherapeutics' acquisition of <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma</a>. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of <a href=\"https://laohu8.com/S/TSBX\">Turnstone Biologics</a> and HilleVax, announced acquisitions of LAVA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and <a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a>, and acted as structuring agent for XenoTherapeutics' acquisition of <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma</a>. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5JJSXp:1","article_id":"2582376301","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582376301","pubTimestamp":1762950640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","XOMA":"标记临床研究","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","EPIX":"ESSA Pharma Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LVTX":"LAVA Therapeutics N.V.","HLVX":"HilleVax, Inc.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"XOMA Royalty报告第三季度收入为940万美元，年初至今收入为3840万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XOMA":0.9,"HLVX":0.9,"EPIX":0.9,"LVTX":0.9,"NDAQ":0.9},"content_text":"XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n    \n\n        XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}